Regeneus Ltd (ASX:RGS) Quarterly Report
Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today released its quarterly cashflow report for the period ending 30 September 2019 (Q1 FY20).
View in Other Languages
Regeneus Ltd
ASX:RGS ISIN:AU000000RGS6
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.
News
Regeneus Ltd (ASX:RGS) Annual Report 2019
Regeneus Ltd (ASX:RGS) is a Sydney Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell cell-based therapies to address significant unmet medical needs in the human health markets.
Regeneus Ltd (ASX:RGS) Receives A$1.5 million in R&D Tax Incentives
Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, has received $1.5 million in R&D Tax Incentives from the Australian Tax Office for FY19.
Regeneus Ltd (ASX:RGS) Financial Report - Year Ended 30 June 2019
Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, releases its financial results for the financial year ended 30 June 2019 (FY2019).
Regeneus Ltd (ASX:RGS) Appoints International Directors for Global Growth
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the appointment of John Chiplin, PhD and Alan W. Dunton, M.D. to its Board of Directors, effective 29 April 2019 as independent, Non-Executive Directors.
Regeneus Ltd (ASX:RGS) Quarterly Results
Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 March, 2019.
Regeneus Ltd (ASX:RGS) Half-Year Report
Regeneus (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company developing a portfolio of novel cell-based therapies targeting significant unmet medical needs in human and animal health, with an initial focus on osteoarthritis, neuropathic pain and dermatology. The Company's product pipeline is underpinned by proprietary stem cell technologies.
Regeneus Ltd (ASX:RGS) Directors Provide $2.5M Loan to Extend Funding Runway
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that its Board of Directors have put in place loan funding of $2.5m to extend the Company's funding runway for the development and licensing of its clinical assets.
Regeneus Ltd (ASX:RGS) Quarterly Report
Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 December 2018.
Regeneus Ltd (ASX:RGS) New CEO Appointed to Accelerate Global Growth
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that it has appointed Leo Lee as the company's new Chief Executive Officer and member of Board of Directors, effective immediately. Leo will succeed the outgoing CEO, John Martin, after 10 years of valuable service to the company.
###
124,653 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 205) (Last 30 Days: 1033) (Since Published: 57214)
Company Reports
Response to ASX Appendix 4C Query- Appendix 4C - Quarterly
- Appendix 4G and Corporate Governance Statement
- Notice of Annual General Meeting / Proxy Form
- Change of Registered Office and Principal Place of Business
- Change of interests of substantial holder - Graham Vesey
- Notice of initial substantial holder - Leo Lee
- Date of AGM
- Appendix 3B
- Appendix 3Y - Barry Sechos
Latest Videos
Presentations
Research Report
Quarterly Report
Annual Report
